<DOC>
	<DOCNO>NCT02910440</DOCNO>
	<brief_summary>The primary objective study compare efficacy DCL-101 GoLYTELY prepare large bowel colonoscopy . Additional secondary objective compare safety DCL-101 GoLYTELY prepare large bowel colonoscopy compare tolerability DCL-101 GoLYTELY prepare large bowel colonoscopy .</brief_summary>
	<brief_title>A Safety Efficacy Study DCL-101 Compared GoLyTELY</brief_title>
	<detailed_description />
	<criteria>1 . Male nonpregnant , nonlactating female , 18 75 year age . Females child bear potential must negative urine pregnancy test prior randomization , must use hormonal ( oral , implantable injectable ) barrier method birth control throughout study . Females unable bear child must documentation source record ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . 2 . Routine , nonurgent , screen surveillance colonoscopy indicate schedule . 3 . Ability subject participate fully aspects clinical trial , include ability willingness swallow capsule . 4 . Informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization obtain documented subject prior start studyspecific procedure . 1 . Known hypersensitivity allergy component GoLYTELY DCL101 2 . Actual suspect ileus , gastrointestinal obstruction major structural gastrointestinal disorder , esophageal stricture , gastric retention , bowel perforation , toxic colitis , ischemic colitis , infectious colitis , toxic megacolon , inflammatory bowel disease . Diverticulitis within past 6 week 3 . Current former tobacco user 4 . Prior colorectal surgery , esophageal surgery , gastric surgery . This include colectomy past , colostomy , ulcer surgery ( antrectomy pyloroplasty ) bariatric surgery , include lap band fundoplication 5 . Chronic constipation , gastroparesis , esophageal motility disorder gut dysmotility disorder 6 . Requiring medication administration schedule safely alter compatible bowel preparation 7 . Current history within past year ongoing clinically relevant electrocardiogram abnormality 8 . Clinically significant electrolyte abnormality Screening , define range normal central laboratory 9 . Significant psychiatric illness 10 . Renal failure chronic kidney disease ( creatinine clearance le 50 mL/min , unstable angina , acute coronary syndrome/congestive heart failure ( New York Heart Association Functional Classification grade III IV ) , ascites 11 . Received investigational therapy within 60 day randomization 12 . Blood donation within 56 day prior randomization 13 . Plasma donation within 7 day prior randomization 14 . Received luminal contrast agent barium watersoluble oral contrast agent within 21 day prior randomization 15 . Known impaired gag reflex , prone regurgitation aspiration 16 . Serious underlying disease opinion investigator may interfere subject 's ability participate fully study 17 . History alcohol drug abuse opinion investigator may interfere subject 's ability comply study procedures 18 . Pregnant lactate woman 19 . Prior enrolment current study receive study treatment 20 . Cognitive barrier opinion investigator may interfere subject 's ability participate fully study 21 . Inability either read understand English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>